These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25758549)

  • 41. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).
    Landolt K; Rössler W; Ajdacic-Gross V; Derks EM; Libiger J; Kahn RS; Fleischhacker WW;
    Schizophr Res; 2016 Apr; 172(1-3):145-51. PubMed ID: 26922655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment response of neurological soft signs in drug-naïve patients with a first psychotic episode.
    Cuesta MJ; Campos MS; García-Jalón E; Sánchez-Torres AM; Peralta V
    Schizophr Res; 2012 Aug; 139(1-3):144-50. PubMed ID: 22682370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.
    Demjaha A; Lappin JM; Stahl D; Patel MX; MacCabe JH; Howes OD; Heslin M; Reininghaus UA; Donoghue K; Lomas B; Charalambides M; Onyejiaka A; Fearon P; Jones P; Doody G; Morgan C; Dazzan P; Murray RM
    Psychol Med; 2017 Aug; 47(11):1981-1989. PubMed ID: 28395674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes.
    Chanpattana W; Kramer BA
    Schizophr Res; 2003 Sep; 63(1-2):189-93. PubMed ID: 12892873
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
    Takeuchi H; Siu C; Remington G; Fervaha G; Zipursky RB; Foussias G; Agid O
    Neuropsychopharmacology; 2019 May; 44(6):1036-1042. PubMed ID: 30514883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 3-year prospective study of neurological soft signs in first-episode schizophrenia.
    Chen EY; Hui CL; Chan RC; Dunn EL; Miao MY; Yeung WS; Wong CK; Chan WF; Tang WN
    Schizophr Res; 2005 Jun; 75(1):45-54. PubMed ID: 15820323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Moving forward: distinct sensorimotor abnormalities predict clinical outcome after 6 months in patients with schizophrenia.
    Sambataro F; Fritze S; Rashidi M; Topor CE; Kubera KM; Wolf RC; Hirjak D
    Eur Neuropsychopharmacol; 2020 Jul; 36():72-82. PubMed ID: 32522386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neurological soft signs in adolescents with first episode psychosis.
    Zabala A; Robles O; Parellada M; Moreno DM; Ruiz-Sancho A; Burdalo M; Medina O; Arango C
    Eur Psychiatry; 2006 Jul; 21(5):283-7. PubMed ID: 16360308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment.
    Scheffler F; Phahladira L; Luckhoff H; du Plessis S; Asmal L; Kilian S; Forti MD; Murray R; Emsley R
    Psychiatry Res; 2021 Aug; 302():114022. PubMed ID: 34052461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurological soft signs in first-episode psychosis: a systematic review.
    Dazzan P; Murray RM
    Br J Psychiatry Suppl; 2002 Sep; 43():s50-7. PubMed ID: 12271801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time course and biologic correlates of treatment response in first-episode schizophrenia.
    Lieberman J; Jody D; Geisler S; Alvir J; Loebel A; Szymanski S; Woerner M; Borenstein M
    Arch Gen Psychiatry; 1993 May; 50(5):369-76. PubMed ID: 8098203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study.
    Millgate E; Smart SE; Pardiñas AF; Kravariti E; Ajnakina O; Kępińska AP; Andreassen OA; Barnes TRE; Berardi D; Crespo-Facorro B; D'Andrea G; Demjaha A; Di Forti M; Doody GA; Kassoumeri L; Ferchiou A; Guidi L; Joyce EM; Lastrina O; Melle I; Pignon B; Richard JR; Simonsen C; Szöke A; Tarricone I; Tortelli A; Vázquez-Bourgon J; Murray RM; Walters JTR; MacCabe JH;
    Schizophr Res; 2023 May; 255():173-181. PubMed ID: 37001392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hippocampal subfield volumes and change in body mass over 12 months of treatment in first-episode schizophrenia spectrum disorders.
    Luckhoff HK; du Plessis S; Kilian S; Asmal L; Scheffler F; Phahladira L; Olivier RM; Emsley R
    Psychiatry Res Neuroimaging; 2020 Jun; 300():111084. PubMed ID: 32388386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study.
    Millgate E; Griffiths K; Egerton A; Kravariti E; Casetta C; Deakin B; Drake R; Howes OD; Kassoumeri L; Khan S; Lankshear S; Lees J; Lewis S; Mikulskaya E; Oloyede E; Owens R; Pollard R; Rich N; Smart S; Segev A; Verena Sendt K; MacCabe J;
    BMJ Open; 2022 Nov; 12(11):e062570. PubMed ID: 36410817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive markers of short-term clinical outcome in first-episode psychosis.
    Bodnar M; Malla A; Joober R; Lepage M
    Br J Psychiatry; 2008 Oct; 193(4):297-304. PubMed ID: 18827291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia.
    Fulford D; Piskulic D; Addington J; Kane JM; Schooler NR; Mueser KT
    Schizophr Bull; 2018 Feb; 44(2):369-377. PubMed ID: 28981811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determinants of neurological dysfunction in first episode schizophrenia.
    Browne S; Clarke M; Gervin M; Lane A; Waddington JL; Larkin C; O'Callaghan E
    Psychol Med; 2000 Nov; 30(6):1433-41. PubMed ID: 11097083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The 2-year stability of neurological soft signs after a first episode of non-affective psychosis.
    Boks MP; Selten JP; Leask S; Van den Bosch RJ
    Eur Psychiatry; 2006 Jul; 21(5):288-90. PubMed ID: 16380235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increasing medication adherence and income assistance access for first-episode psychosis patients.
    Randall J; Chateau D; Bolton JM; Smith M; Katz L; Burland E; Taylor C; Nickel NC; Enns J; Katz A; Brownell M;
    PLoS One; 2017; 12(6):e0179089. PubMed ID: 28591137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic efficacy of flupenthixol decanoate in schizoaffective disorder: a clinical evaluation.
    Singh AN
    J Int Med Res; 1984; 12(1):17-22. PubMed ID: 6692965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.